Antivirals for adult patients hospitalised with SARS-CoV-2 infection : a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn trial
© 2023 The Authors..
Background: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients.
Methods: REVOLUTIOn is a randomised, parallel, blinded, multistage, superiority and placebo controlled randomised trial conducted in 35 centres in Brazil. We include patients aged 18 years or older admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, symptoms onset 9 days or less and SpO2 94% or lower at room air were eligible. All participants were randomly allocated to receive either atazanavir, daclatasvir or sofosbuvir/daclatasvir or placebo for 10 days. The primary outcome was the decay rate (slope) of the SARS-CoV-2 viral load logarithm assessed in the modified intention to-treat population. This trial was registered with ClinicalTrials.gov, number NCT04468087.
Findings: Between February 09, 2021, and August 04, 2021, 255 participants were enrolled and randomly assigned to atazanavir (n = 64), daclatasvir (n = 66), sofosbuvir/daclatasvir (n = 67) or placebo (n = 58). Compared to placebo group, the change from baseline to day 10 in log viral load was not significantly different for any of the treatment groups (0.05 [95% CI, -0.03 to 0.12], -0.02 [95% CI, -0.09 to 0.06], and -0.03 [95% CI, -0.11 to 0.04] for atazanavir, daclatasvir and sofosbuvir/daclatasvir groups respectively). There was no significant difference in the occurrence of serious adverse events between treatment groups.
Interpretation: No significant reduction in viral load was observed from the use of atazanavir, daclatasvir or sofosbuvir/daclatasvir compared to placebo in hospitalised COVID-19 patients who need oxygen support with symptoms onset 9 days or less.
Funding: Ministério da Ciência, Tecnologia e Inovação (MCTI) - Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ); Cia Latino-Americana de Medicamentos (Clamed); Cia Industrial H. Carlos Schneider (Ciser); Hospital Research Foundation Incorporation, Australia, HCor São Paulo; Blanver Farmoquímica; Instituto de Tecnologia em Fármacos (Farmanguinhos) da Fundação Oswaldo Cruz (Fiocruz); Coordenação Geral de Planejamento Estratégico (Cogeplan)/Fiocruz; and Fundação de apoio a Fiocruz (Fiotec, VPGDI-054-FIO-20-2-13).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Lancet regional health. Americas - 20(2023) vom: 15. Apr., Seite 100466 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory failure |
|---|
| Anmerkungen: |
Date Revised 14.03.2023 published: Print-Electronic ClinicalTrials.gov: NCT04468087 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lana.2023.100466 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354141139 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354141139 | ||
| 003 | DE-627 | ||
| 005 | 20231226061600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lana.2023.100466 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354141139 | ||
| 035 | |a (NLM)36908503 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maia, Israel S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antivirals for adult patients hospitalised with SARS-CoV-2 infection |b a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04468087 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients | ||
| 520 | |a Methods: REVOLUTIOn is a randomised, parallel, blinded, multistage, superiority and placebo controlled randomised trial conducted in 35 centres in Brazil. We include patients aged 18 years or older admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, symptoms onset 9 days or less and SpO2 94% or lower at room air were eligible. All participants were randomly allocated to receive either atazanavir, daclatasvir or sofosbuvir/daclatasvir or placebo for 10 days. The primary outcome was the decay rate (slope) of the SARS-CoV-2 viral load logarithm assessed in the modified intention to-treat population. This trial was registered with ClinicalTrials.gov, number NCT04468087 | ||
| 520 | |a Findings: Between February 09, 2021, and August 04, 2021, 255 participants were enrolled and randomly assigned to atazanavir (n = 64), daclatasvir (n = 66), sofosbuvir/daclatasvir (n = 67) or placebo (n = 58). Compared to placebo group, the change from baseline to day 10 in log viral load was not significantly different for any of the treatment groups (0.05 [95% CI, -0.03 to 0.12], -0.02 [95% CI, -0.09 to 0.06], and -0.03 [95% CI, -0.11 to 0.04] for atazanavir, daclatasvir and sofosbuvir/daclatasvir groups respectively). There was no significant difference in the occurrence of serious adverse events between treatment groups | ||
| 520 | |a Interpretation: No significant reduction in viral load was observed from the use of atazanavir, daclatasvir or sofosbuvir/daclatasvir compared to placebo in hospitalised COVID-19 patients who need oxygen support with symptoms onset 9 days or less | ||
| 520 | |a Funding: Ministério da Ciência, Tecnologia e Inovação (MCTI) - Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ); Cia Latino-Americana de Medicamentos (Clamed); Cia Industrial H. Carlos Schneider (Ciser); Hospital Research Foundation Incorporation, Australia, HCor São Paulo; Blanver Farmoquímica; Instituto de Tecnologia em Fármacos (Farmanguinhos) da Fundação Oswaldo Cruz (Fiocruz); Coordenação Geral de Planejamento Estratégico (Cogeplan)/Fiocruz; and Fundação de apoio a Fiocruz (Fiotec, VPGDI-054-FIO-20-2-13) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute respiratory failure | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a Atazanavir | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Daclatasvir | |
| 650 | 4 | |a Hypoxemia | |
| 650 | 4 | |a Randomised controlled trial | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a Sofosbuvir | |
| 650 | 4 | |a Viral load | |
| 700 | 1 | |a Marcadenti, Aline |e verfasserin |4 aut | |
| 700 | 1 | |a Veiga, Viviane C |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Tamiris A |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Samara P C |e verfasserin |4 aut | |
| 700 | 1 | |a Carollo, Mariana B S |e verfasserin |4 aut | |
| 700 | 1 | |a Negrelli, Karina L |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Jackeline O |e verfasserin |4 aut | |
| 700 | 1 | |a Tramujas, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Abreu-Silva, Erlon O |e verfasserin |4 aut | |
| 700 | 1 | |a Westphal, Glauco A |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Ruthy P |e verfasserin |4 aut | |
| 700 | 1 | |a Horta, Jacques G A |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Deborah C |e verfasserin |4 aut | |
| 700 | 1 | |a Flato, Uri A P |e verfasserin |4 aut | |
| 700 | 1 | |a Paoliello, Ricardo C R |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Camilo |e verfasserin |4 aut | |
| 700 | 1 | |a Zandonai, Cássio L |e verfasserin |4 aut | |
| 700 | 1 | |a Coelho, Juliana C |e verfasserin |4 aut | |
| 700 | 1 | |a Barros, Waldemar C |e verfasserin |4 aut | |
| 700 | 1 | |a Lemos, Juliana C |e verfasserin |4 aut | |
| 700 | 1 | |a Bolan, Renata S |e verfasserin |4 aut | |
| 700 | 1 | |a Dutra, Marcela M |e verfasserin |4 aut | |
| 700 | 1 | |a Gebara, Otavio C E |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Ana T A |e verfasserin |4 aut | |
| 700 | 1 | |a Alencar Filho, Meton S |e verfasserin |4 aut | |
| 700 | 1 | |a Arraes, Jussara A |e verfasserin |4 aut | |
| 700 | 1 | |a Hamamoto, Victor A |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandes, Mauro E |e verfasserin |4 aut | |
| 700 | 1 | |a Golin, Nicole A |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Tiago M |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Renato H N |e verfasserin |4 aut | |
| 700 | 1 | |a Damiani, Lucas P |e verfasserin |4 aut | |
| 700 | 1 | |a Zampieri, Fernando G |e verfasserin |4 aut | |
| 700 | 1 | |a Gesto, João |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Flávia R |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, Régis G |e verfasserin |4 aut | |
| 700 | 1 | |a Azevedo, Luciano C P |e verfasserin |4 aut | |
| 700 | 1 | |a Avezum, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Renato D |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Thiago M L |e verfasserin |4 aut | |
| 700 | 1 | |a Berwanger, Otávio |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalcanti, Alexandre B |e verfasserin |4 aut | |
| 700 | 0 | |a BRICNet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet regional health. Americas |d 2021 |g 20(2023) vom: 15. Apr., Seite 100466 |w (DE-627)NLM329305697 |x 2667-193X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g day:15 |g month:04 |g pages:100466 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lana.2023.100466 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |b 15 |c 04 |h 100466 | ||